PCSK9 inhibition to reduce cardiovascular disease risk: Recent findings from the biology of PCSK9

Hagai Tavori, Ilaria Giunzioni, Sergio Fazio

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    Purpose of review Review novel insights into the biology of proprotein convertase subtilisin/kexin 9 (PCSK9) that may explain the extreme efficiency of PCSK9 inhibition and the unexpected metabolic effects resulting from PCSK9 monoclonal antibody therapy, and may identify additional patients as target of therapy. Recent findings For over 20 years, the practical knowledge of cholesterol metabolism has centered around cellular mechanisms, and around the idea that statin therapy is the essential step to control metabolic abnormalities for cardiovascular risk management. This view has been embraced by the recent AHA/ACC guidelines, but is being challenged by recent studies including nonstatin medications and by the development of a new class of cholesterol-lowering agents that seems destined to early US Food and Drug Administration approval. The discovery of PCSK9 - a circulating protein that regulates hepatic low-density lipoprotein (LDL) receptor and serum LDL cholesterol levels - has led to a race for its therapeutic inhibition. Recent findings on PCSK9 regulation and pleiotropic effects will help identify additional patient groups likely to benefit from the inhibitory therapy and unravel the full potential of PCSK9 inhibition therapy. Summary Injectable human monoclonal antibodies to block the interaction between PCSK9 and LDL receptor are demonstrating extraordinary efficacy (LDL reductions of up to 70%) and almost the absence of any side-effects. A more moderate effect is seen on other lipoprotein parameters, with the exception of lipoprotein(a) levels. We describe mechanisms that can explain the effect on lipoprotein(a), predict a potential effect on postprandial triglyderides, and suggest a new category of patients for anti-PCSK9 therapy.

    Original languageEnglish (US)
    Pages (from-to)126-132
    Number of pages7
    JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
    Volume22
    Issue number2
    DOIs
    StatePublished - Apr 7 2015

    Fingerprint

    Proprotein Convertases
    Subtilisin
    Cardiovascular Diseases
    Lipoprotein(a)
    LDL Receptors
    Therapeutics
    Cholesterol
    Monoclonal Antibodies
    Cardiovascular Abnormalities
    Drug Approval
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Risk Management
    LDL Lipoproteins
    LDL Cholesterol
    Lipoproteins
    Guidelines
    Food
    Injections

    Keywords

    • LDL-cholesterol
    • LDL-receptor
    • lipoprotein(a)
    • PCSK9 inhibition
    • triglycerides

    ASJC Scopus subject areas

    • Endocrinology
    • Endocrinology, Diabetes and Metabolism
    • Internal Medicine
    • Nutrition and Dietetics

    Cite this

    PCSK9 inhibition to reduce cardiovascular disease risk : Recent findings from the biology of PCSK9. / Tavori, Hagai; Giunzioni, Ilaria; Fazio, Sergio.

    In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 22, No. 2, 07.04.2015, p. 126-132.

    Research output: Contribution to journalArticle

    @article{c4ff10747bb047ecb26978fda4f23084,
    title = "PCSK9 inhibition to reduce cardiovascular disease risk: Recent findings from the biology of PCSK9",
    abstract = "Purpose of review Review novel insights into the biology of proprotein convertase subtilisin/kexin 9 (PCSK9) that may explain the extreme efficiency of PCSK9 inhibition and the unexpected metabolic effects resulting from PCSK9 monoclonal antibody therapy, and may identify additional patients as target of therapy. Recent findings For over 20 years, the practical knowledge of cholesterol metabolism has centered around cellular mechanisms, and around the idea that statin therapy is the essential step to control metabolic abnormalities for cardiovascular risk management. This view has been embraced by the recent AHA/ACC guidelines, but is being challenged by recent studies including nonstatin medications and by the development of a new class of cholesterol-lowering agents that seems destined to early US Food and Drug Administration approval. The discovery of PCSK9 - a circulating protein that regulates hepatic low-density lipoprotein (LDL) receptor and serum LDL cholesterol levels - has led to a race for its therapeutic inhibition. Recent findings on PCSK9 regulation and pleiotropic effects will help identify additional patient groups likely to benefit from the inhibitory therapy and unravel the full potential of PCSK9 inhibition therapy. Summary Injectable human monoclonal antibodies to block the interaction between PCSK9 and LDL receptor are demonstrating extraordinary efficacy (LDL reductions of up to 70{\%}) and almost the absence of any side-effects. A more moderate effect is seen on other lipoprotein parameters, with the exception of lipoprotein(a) levels. We describe mechanisms that can explain the effect on lipoprotein(a), predict a potential effect on postprandial triglyderides, and suggest a new category of patients for anti-PCSK9 therapy.",
    keywords = "LDL-cholesterol, LDL-receptor, lipoprotein(a), PCSK9 inhibition, triglycerides",
    author = "Hagai Tavori and Ilaria Giunzioni and Sergio Fazio",
    year = "2015",
    month = "4",
    day = "7",
    doi = "10.1097/MED.0000000000000137",
    language = "English (US)",
    volume = "22",
    pages = "126--132",
    journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
    issn = "1752-296X",
    publisher = "Lippincott Williams and Wilkins",
    number = "2",

    }

    TY - JOUR

    T1 - PCSK9 inhibition to reduce cardiovascular disease risk

    T2 - Recent findings from the biology of PCSK9

    AU - Tavori, Hagai

    AU - Giunzioni, Ilaria

    AU - Fazio, Sergio

    PY - 2015/4/7

    Y1 - 2015/4/7

    N2 - Purpose of review Review novel insights into the biology of proprotein convertase subtilisin/kexin 9 (PCSK9) that may explain the extreme efficiency of PCSK9 inhibition and the unexpected metabolic effects resulting from PCSK9 monoclonal antibody therapy, and may identify additional patients as target of therapy. Recent findings For over 20 years, the practical knowledge of cholesterol metabolism has centered around cellular mechanisms, and around the idea that statin therapy is the essential step to control metabolic abnormalities for cardiovascular risk management. This view has been embraced by the recent AHA/ACC guidelines, but is being challenged by recent studies including nonstatin medications and by the development of a new class of cholesterol-lowering agents that seems destined to early US Food and Drug Administration approval. The discovery of PCSK9 - a circulating protein that regulates hepatic low-density lipoprotein (LDL) receptor and serum LDL cholesterol levels - has led to a race for its therapeutic inhibition. Recent findings on PCSK9 regulation and pleiotropic effects will help identify additional patient groups likely to benefit from the inhibitory therapy and unravel the full potential of PCSK9 inhibition therapy. Summary Injectable human monoclonal antibodies to block the interaction between PCSK9 and LDL receptor are demonstrating extraordinary efficacy (LDL reductions of up to 70%) and almost the absence of any side-effects. A more moderate effect is seen on other lipoprotein parameters, with the exception of lipoprotein(a) levels. We describe mechanisms that can explain the effect on lipoprotein(a), predict a potential effect on postprandial triglyderides, and suggest a new category of patients for anti-PCSK9 therapy.

    AB - Purpose of review Review novel insights into the biology of proprotein convertase subtilisin/kexin 9 (PCSK9) that may explain the extreme efficiency of PCSK9 inhibition and the unexpected metabolic effects resulting from PCSK9 monoclonal antibody therapy, and may identify additional patients as target of therapy. Recent findings For over 20 years, the practical knowledge of cholesterol metabolism has centered around cellular mechanisms, and around the idea that statin therapy is the essential step to control metabolic abnormalities for cardiovascular risk management. This view has been embraced by the recent AHA/ACC guidelines, but is being challenged by recent studies including nonstatin medications and by the development of a new class of cholesterol-lowering agents that seems destined to early US Food and Drug Administration approval. The discovery of PCSK9 - a circulating protein that regulates hepatic low-density lipoprotein (LDL) receptor and serum LDL cholesterol levels - has led to a race for its therapeutic inhibition. Recent findings on PCSK9 regulation and pleiotropic effects will help identify additional patient groups likely to benefit from the inhibitory therapy and unravel the full potential of PCSK9 inhibition therapy. Summary Injectable human monoclonal antibodies to block the interaction between PCSK9 and LDL receptor are demonstrating extraordinary efficacy (LDL reductions of up to 70%) and almost the absence of any side-effects. A more moderate effect is seen on other lipoprotein parameters, with the exception of lipoprotein(a) levels. We describe mechanisms that can explain the effect on lipoprotein(a), predict a potential effect on postprandial triglyderides, and suggest a new category of patients for anti-PCSK9 therapy.

    KW - LDL-cholesterol

    KW - LDL-receptor

    KW - lipoprotein(a)

    KW - PCSK9 inhibition

    KW - triglycerides

    UR - http://www.scopus.com/inward/record.url?scp=84926375797&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84926375797&partnerID=8YFLogxK

    U2 - 10.1097/MED.0000000000000137

    DO - 10.1097/MED.0000000000000137

    M3 - Article

    C2 - 25692926

    AN - SCOPUS:84926375797

    VL - 22

    SP - 126

    EP - 132

    JO - Current Opinion in Endocrinology, Diabetes and Obesity

    JF - Current Opinion in Endocrinology, Diabetes and Obesity

    SN - 1752-296X

    IS - 2

    ER -